BusinessAchillion Announces ACH-4471 Receives Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of C3 GlomerulopathyBy Nasdaq OMXFeb 26, 2018, 11:05 AM UTC
BusinessProtalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017By Nasdaq OMXMar 9, 2017, 12:30 PM UTC
BusinessXOMA Announces Significant Step Toward Initiating Pediatric Phase 2 Clinical Study for XOMA 358 in Children with Congenital HyperinsulinismBy Nasdaq OMXOct 19, 2016, 1:01 PM UTC
BusinessAchillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of Hematology and Nomination of ACH-4471, a Novel Small Molecule Factor D Inhibitor, for Clinical DevelopmentBy Nasdaq OMXDec 5, 2015, 10:00 PM UTC
